SCHEMBL1815467

SCHEMBL1815467

[2H]C([2H])([2H])C(Cc1ccccc1)NC(=O)c1c(F)c(F)c(F)c(F)c1F

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.54
RAB9A P51151 4/20 0.54
TSHR P16473 1/20 0.51
SMN1; SMN2 Q16637 2/20 0.50
PKM P14618 1/20 0.50
TP53 P04637 3/20 0.48
KMT2A Q03164 2/20 0.48
LMNA P02545 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.45
MEN1 O00255 1/20 0.44
GAA P10253 1/20 0.44
TAAR1 Q96RJ0 1/20 0.43
POLB P06746 1/20 0.43
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41
CTRB1 P17538 2/20 0.41
TAS1R3 Q7RTX0 1/20 0.41
TAS1R1 Q7RTX1 1/20 0.41
TAS1R2 Q8TE23 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28965815 0.78 L3MBTL1 (0.67) TSHRL3MBTL1
SCHEMBL28965814 0.78 L3MBTL1 (0.67) TSHRL3MBTL1
SCHEMBL1811166 0.75 SMN1; SMN2 (0.55) NPC1RAB9ATSHRSMN1; SMN2PKM
SCHEMBL4166540 0.73 L3MBTL1 (0.68) KMT2AL3MBTL1
SCHEMBL1816088 0.73 ACACB (0.56) NPC1RAB9ASMN1; SMN2PKMTP53
SCHEMBL14654946 0.71 NPC1 (1.00) NPC1RAB9ASMN1; SMN2TP53KMT2A
SCHEMBL23099741 0.71 NPC1 (0.74) NPC1RAB9ASMN1; SMN2TP53KMT2A
SCHEMBL24862861 0.71 POLB (0.74) NPC1RAB9ASMN1; SMN2TP53KMT2A
SCHEMBL23099898 0.70 NPC1 (0.60) NPC1RAB9ASMN1; SMN2TP53KMT2A
SCHEMBL11949543 0.70 RAB9A (0.79) NPC1RAB9ASMN1; SMN2TP53KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8314269-B2 N-(1-methyl-2phenylethyl)benzamide derivatives BAYER CROPSCIENCE AG (DE) 2012-11-20 US claimed
US-20110237678-A1 N-(1-METHYL-2PHENYLETHYL)BENZAMIDE DERIVATIVES BAYER CROPSCIENCE AG (DE) 2011-09-29 US claimed
US-20090156682-A1 N-(1-Methyl-2Phenylethyl)Benzamide Derivatives BAYER INTELLECTUAL PROPERTY GMBH (DE) 2009-06-18 US claimed
EP-1960350-A1 NEW N-(1-METHYL-2PHENYLETHYL)BENZAMIDE DERIVATIVES BAYER CROPSCIENCE SA (FR) 2008-08-27 EP claimed
WO-2007060162-A1 NEW N-(1-METHYL-2PHENYLETHYL)BENZAMIDE DERIVATIVES BAYER CROPSCIENCE SA (FR) 2007-05-31 WO claimed
US-8314269-B2 N-(1-methyl-2phenylethyl)benzamide derivatives BAYER CROPSCIENCE AG (DE) 2012-11-20 US disclosed
US-20110237678-A1 N-(1-METHYL-2PHENYLETHYL)BENZAMIDE DERIVATIVES BAYER CROPSCIENCE AG (DE) 2011-09-29 US disclosed
US-7951973-B2 N-(1-methyl-2Phenylethyl)benzamide derivatives BAYER CROPSCIENCE AG (DE) 2011-05-31 US disclosed
US-20090156682-A1 N-(1-Methyl-2Phenylethyl)Benzamide Derivatives BAYER INTELLECTUAL PROPERTY GMBH (DE) 2009-06-18 US disclosed
EP-1960350-A1 NEW N-(1-METHYL-2PHENYLETHYL)BENZAMIDE DERIVATIVES BAYER CROPSCIENCE SA (FR) 2008-08-27 EP disclosed
WO-2007060162-A1 NEW N-(1-METHYL-2PHENYLETHYL)BENZAMIDE DERIVATIVES BAYER CROPSCIENCE SA (FR) 2007-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156682-A1 N-(1-Methyl-2Phenylethyl)Benzamide Derivatives CYP51A1, CYP1A2, CYP1A1 NPC1 175/4885RAB9A 1825/4885TSHR 3900/4885
US-20110237678-A1 N-(1-METHYL-2PHENYLETHYL)BENZAMIDE DERIVATIVES CYP51A1, CYP1A2, CYP1A1 NPC1 184/4885RAB9A 1885/4885TSHR 3926/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.